STOCK TITAN

Arbutus Biopharma Corp - ABUS STOCK NEWS

Welcome to our dedicated news page for Arbutus Biopharma (Ticker: ABUS), a resource for investors and traders seeking the latest updates and insights on Arbutus Biopharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Arbutus Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Arbutus Biopharma's position in the market.

Rhea-AI Summary
Arbutus Biopharma to present clinical and preclinical data at The Liver Meeting® 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.61%
Tags
none
-
Rhea-AI Summary
Arbutus Biopharma announces pipeline updates, focusing on HBV assets imdusiran and AB-101, discontinuing coronavirus and oral RNA destabilizer programs. Cash runway extended through Q3 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.73%
Tags
clinical trial
-
Rhea-AI Summary
Arbutus Biopharma to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
conferences earnings
-
Rhea-AI Summary
Arbutus Biopharma appoints Melissa V. Rewolinski, PhD, to its board of directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
News
Rhea-AI Summary
Arbutus Biopharma announces the appointment of Dr. Karen Sims as Chief Medical Officer and Mr. Christopher Naftzger as General Counsel and Chief Compliance Officer. Dr. Sims has played a key role in the development of AB-729, the company's lead therapeutic, and will lead the clinical team. Mr. Naftzger brings over a decade of experience as in-house general counsel for life science companies. Arbutus also thanks Dr. Elizabeth Howard for her contributions and announces the grant of an option to Mr. Naftzger as an inducement award.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.87%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.87%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
conferences
Arbutus Biopharma Corp

Nasdaq:ABUS

ABUS Rankings

ABUS Stock Data

463.09M
115.49M
23.43%
44.06%
2.3%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Warminster

About ABUS

arbutus biopharma corporation (nasdaq:abus) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis b infection, a disease of the liver caused by hepatitis b virus (hbv). we are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the hbv treatment landscape and cure hepatitis b virus disease. in addition to our hbv assets, we are developing a pipeline of programs that leverage our expertise in rna interference (rnai) therapeutics and our lipid nanoparticle (lnp) technology.